Latest PCSK9 Stories

redOrbit Staff & Wire Reports - Your Universe Online Researchers from the University of Michigan (UMich) have found a new genetic target which they believe could be used instead of -- or along with -- statins to help lower a person’s cholesterol. Scientists working in the lab of David Ginsburg at the Ann Arbor-based university’s Life Sciences Institute managed to inhibit the action of a gene responsible for transporting a protein known to interfere with the liver’s ability to...

THOUSAND OAKS, Calif., Nov. 2, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present data from four Phase 2 trials of AMG 145, an investigational fully human monoclonal antibody directed against PCSK9, a protein that reduces the liver's ability to remove low density lipoprotein cholesterol (LDL-C), or "bad" cholesterol from the blood, at the upcoming American Heart Association (AHA) Scientific Sessions 2012. Selected abstracts of interest that will be presented at the meeting...

PARIS and TARRYTOWN, N.Y., Oct. 31, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results from a Phase 2 trial of SAR236553/REGN727 in patients with primary hypercholesterolemia were published in the October 31, 2012 issue of the New England Journal of Medicine. The study enrolled patients with primary hypercholesterolemia with elevated LDL-C (greater than or equal to 100 mg/dL) who were on a...

PARIS and TARRYTOWN, New York, July 20, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that several trials within ODYSSEY, the Phase 3 clinical program of SAR236553/REGN727, have initiated patient enrollment. SAR236553/REGN727 is a potential first-in-class, subcutaneously administered, fully-human antibody that lowers low-density lipoprotein (LDL) cholesterol by targeting PCSK9 (proprotein convertase...

PARIS and TARRYTOWN, New York, May 26, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced additional positive results from a Phase 2 trial of SAR236553/REGN727 (Study 1003, NTC01266876) in patients with heterozygous familial hypercholesterolemia (heFH). SAR236553/REGN727 is a subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) in clinical...

New research shows SAR236553/REGN727 reduces LDL by up to 72 percent in patients A novel monoclonal antibody identified in a new study dramatically lowered circulating LDL cholesterol by 40 percent to 72 percent, a development with potential to provide a new option for patients who are resistant to cholesterol-lowering drugs such as statins or to the current standard of care, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session. The...

PARIS and TARRYTOWN, N.Y., March 26, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology's (ACC) 61st Annual Scientific Meeting in Chicago. To view the...

(Ivanhoe Newswire) – Researchers are trying to find the answers to cholesterol! In three phase 1 trials, they analyzed how PCSK9 binds to LDL receptors and will lead to their accelerated degradation and to increased LDL cholesterol levels. In 2003, a study was performed on two families with autosomal dominant hypercholesterolemia that is associated with gain-of-function mutations in PCSK9 (proprotein convertase subtilisin/kexin 9), one of the serine proteases. The patients involved in...

TARRYTOWN, N.Y., March 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results of the Phase 1 clinical program with their investigational product REGN727/SAR236553, a novel, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9 serine protease) were published in the March 22, 2012 issue of the New England Journal of Medicine. The primary author of the article,...